Phaseline

Targets › PAH

PAH (Phenylalanine-4-hydroxylase): drug programs, companies and trials

12 programs from 10 companies in 14 trials: 9 Phase 1, 2 Phase 3, 2 Phase 4, 1 Phase 2; Metabolic and endocrine, Cardiovascular, Genitourinary; next expected readout Apr 2027.

Catalyzes the hydroxylation of L-phenylalanine to L-tyrosine. (UniProt, P00439)

Open in Phaseline: the race on PAH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioMarin PharmaceuticalPegvaliase
Phenylalanine ammonia-lyase (PAL) enzyme - degrades phenylalanine to ammonia and trans-cin
PAHPhase 4Phenylketonuria; Phenylketonuria (PKU)Sep 2027
BioMarin PharmaceuticalPalynziq
Pegvaliase (PEGylated recombinant phenylalanine ammonia-lyase)
PAHPhase 4Phenylketonuria–
PTC TherapeuticsSepiapterin
tetrahydrofolate (BH4) cofactor precursor; increases production of tetrahydropterin (BH4)
PAHPhase 3PhenylketonuriaFeb 2031
Emory UniversitySapropterin
Phenylalanine-4-hydroxylase activator
PAHPhase 2Renal Insufficiency, ChronicApr 2027
Chongqing Peg-Bio BiopharmPL54
PEGylated recombinant phenylalanine ammonia-lyase
PAHPhase 1Phenylketonuria (PKU)Jun 2027
Louis MessinaSapropterin
Phenylalanine-4-hydroxylase activator
PAHPhase 1Claudication, IntermittentJul 2027
NGGT (Suzhou) BiotechnologyNGGT002
adeno-associated viral vector with human phenylalanine hydroxylase gene
PAHPhase 1PhenylketonuriasAug 2027
BioMarin PharmaceuticalBMN 307
AAV gene therapy delivering phenylalanine hydroxylase (PAH) gene
PAHPhase 1Phenylketonuria (PKU)Dec 2027
Agios PharmaceuticalsAG-181
Phenylalanine hydroxylase (PAH) activator
PAHPhase 1PhenylketonuriaJan 2028
VA Office of Research and DevelopmentSapropterin
Phenylalanine-4-hydroxylase activator
PAHPhase 1Heart Failure With Preserved Ejection FractionSep 2028
NGGTNGGT002
Adeno-associated viral vector with human phenylalanine hydroxylase gene
PAHPhase 1PhenylketonuriasDec 2030
Sohag UniversitySapropterin Dihydrochloride
Phenylalanine-4-hydroxylase activator
PAHPhase 1Phenylketonuria (PKU)–

Conditions

Phenylketonuria (4) Phenylketonuria (PKU) (4) Phenylketonurias (2) Claudication, Intermittent (2) Heart Failure With Preserved Ejection Fraction (1) Renal Insufficiency, Chronic (1)

Modalities

small molecule (8), protein or peptide (2), other (2)

Companies

BioMarin Pharmaceutical (3) PTC Therapeutics (1) Chongqing Peg-Bio Biopharm (1) Sohag University (1) NGGT (1) Agios Pharmaceuticals (1) VA Office of Research and Development (1) Emory University (1) NGGT (Suzhou) Biotechnology (1) Louis Messina (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.